Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Gyre Therapeutics (GYRE) Receivables - Net (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Receivables - Net for 15 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 58.65% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.1 million through Dec 2025, up 58.65% year-over-year, with the annual reading at $31.1 million for FY2025, 58.65% up from the prior year.
  • Receivables - Net for Q4 2025 was $31.1 million at Gyre Therapeutics, up from $26.1 million in the prior quarter.
  • The five-year high for Receivables - Net was $31.1 million in Q4 2025, with the low at $564000.0 in Q1 2022.
  • Average Receivables - Net over 5 years is $12.8 million, with a median of $15.3 million recorded in 2023.
  • The sharpest move saw Receivables - Net tumbled 45.13% in 2021, then soared 842.57% in 2022.
  • Over 5 years, Receivables - Net stood at $1.8 million in 2021, then skyrocketed by 842.57% to $17.1 million in 2022, then decreased by 11.27% to $15.2 million in 2023, then rose by 28.84% to $19.6 million in 2024, then surged by 58.65% to $31.1 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $31.1 million, $26.1 million, and $25.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.